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Abstract 
 
Mutations in adenine biosynthesis pathway gene ADE1 have been conventionally 
used to score for prion [PSI+] in yeast. If ade1-14 mutant allele is present, which 
contains a premature stop codon, [psi-] yeast appear red on YPD medium due to 
accumulation of a red intermediate compound in the vacuoles. In [PSI+] yeast, partial 
inactivation of the translation termination factor, Sup35 protein, due to its amyloid 
aggregation allows for read-through of the stop codon in the ade1-14 allele and yeast 
appears white as no red intermediate pigment is accumulated. It is known that the 
red color development in ade1 mutant yeast requires cytoplasmic levels of reduced 
glutathione which helps in transport of the intermediate metabolite P-
ribosylaminoimidazole carboxylate (CAIR) into vacuoles that develops red color. 
Here, we hypothesized that amyloid-induced oxidative stress in yeast would deplete 
reduced glutathione levels and thus thwart the development of red color in the ade1 
yeast. Indeed, when we over-expressed amyloid forming human proteins TDP-43, 
Amyloid β-42 & Poly-Gln-103, the otherwise red ade1 mutant yeast, turned to white 
color. Further, the color reverted back to red upon turning off the amyloid expression 
or by growth on media containing reducing agent thereby corroborating that the 
oxidative stress caused the white color. This red/white assay could also be emulated 
in an ade1 yeast having erg6 gene deletion that increases the cell wall permeability. 
Thus, this model would be useful tool for drug-screening against general amyloid-
induced oxidative stress & toxicity in yeast.  
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Nomenclature 
 
Genetic nomenclature 
Gene symbol Definition 
ade1-14 Specific allele or mutation in ADE gene (Adenine) 
his3-200 Specific allele or mutation in HIS gene (Histidine) 
ura3-52 Specific allele or mutation in URA gene (Uracil) 
leu2-3,112 Specific allele or mutation in LEU gene (Leucine) 
trp1-289 Specific allele or mutation in TRP gene (Tryptophan) 
erg6:TRP1 Insertion of functional TRP1 gene at ERG6 locus and erg6 
is non-functional 
[psi-] Decreased efficiency of certain suppression (translational 
read through of stop codons in ade1-14 allele) 
[PSI+] Increased efficiency of certain suppression (translational read 
through of stop codons in ade1-14 allele) 
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Chapter 1 
 
Introduction 
   
 
1.1 Protein misfolding 
Protein folding machinery ensures that the protein is packed into unique, three-
dimensional native conformation to confer its functional activity. Protein folding is 
driven to attain maximum entropy and global energy minimum[1]. This self-
organization of protein into native structure follows through the route of folding 
funnel[2]. Unique protein sequence drives the proteins from state of highest energy 
where the protein is unfolded to obtain lower energy states by local conformational 
arrangement to reach the unique native structure of protein with high entropy (Figure 
1)[2].  
The process is sophisticated and complex owing to the elaborate conventions of 
pathways involved and varying compartments in which it takes place. Inherent 
mutations and environmental agents such as temperature, pH, oxidation state 
contribute to the disruption of protein’s native state resulting in protein unfolding[3]. 
The unfolded proteins, which are energetically unfavorable, seek to attain lower 
energy state causing protein misfolding and aggregation. The unfolded proteins can 
exhibit varying structural conformation from oligomers to amorphous aggregates to 
highly organized fibrils. Initially, misfolded proteins undergo intermolecular contacts 
to get organized into oligomers and form a nucleation core which binds misfolded 
	 2	 	 	 	
monomers reversibly. When a certain threshold critical mass is crossed, they form an 
irreversible large aggregate state with conformational plasticity (Figure 1). Low 
concentration of proteins tends to favor monomeric state whereas high concentration 
of proteins favor aggregation state. 
 
 
Figure 1: Energy state of protein folding and misfolding[2] 
 
1.2 Amyloids and prions 
Amyloid fibrils are stable, highly organized protein aggregates rich in β sheet 
conformation which forms abnormal, insoluble deposits in organs and tissues[4]. 
Conversion of peptide into fibrillar arrangement begins with a lag phase of forming 
nuclei followed by formation of series of metastable, non-fibrillar intermediates such 
as protofibrils. The fibrillar structure of amyloids consist of protofilaments 2-5 nm in 
diameter which can twist to form fibrils which are 7-13 nm wide[5] (Figure 2A). These 
large fibrils accumulate as proteinaceous deposits in amyloid and amyloid-like diseases 
(Figure 2B) [6]. Protofilaments are repeating units of “cross β” structure where β 
sheets are arranged parallel to fibrillar axis and its strands perpendicular to the axis. 
They are organized with an interstrand distance of 4.7 A° and intersheet space 
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distance of 10 A° [6, 7] (Figure 2C). Amyloids are characterized by the apple green 
birefringence with cross polarized light, upon binding to Congo red dye (Figure 2D) 
and increase in fluorescence upon binding to ThioflavinT (Figure 2E) [6]. Amyloids 
form detergent insoluble aggregates (Figure 2F) [8] which show partial resistance to 
proteinase K. Hydrophobic amino acids, β sheet predisposition and low net charge 
can enhance the formation of amyloids. 
 
Figure 2: Amyloid fibrils and characteristics [5-8]. 
Amyloid deposits are reported in several neurodegenerative diseases including 
Alzheimer’s and Parkinson’s [3] (Table 1.1). Amyloids cause toxicity via number of 
pathways affecting Endoplasmic reticulum (ER) stress, Reactive Oxygen Species 
(ROS) and causing pores in lipid bilayers. 
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Table 1.1: Neurodegenerative diseases and associated proteins 
 
Prions are infectious, self-propagating, transmissible protein isoforms that can fold in 
structurally distinct ways and cause diseases [9]. Prions are capable of transmitting 
their misfolded protein into a healthy species causing the properly folded protein 
structure to misfold and aggregate. Prions are reported in several organisms 
[10](Table 1.2). 
 
Table 1.2: Prion diseases and host 
Prion disease Host 
Familial Cruetzfeld Jacob Disease (CJD) Human 
Scrapie Sheep 
Bovine spongiform encephalopathy (BSE) Cattle 
Transmissible mink encephalopathy 
(TME)  
Mink 
Kuru  Fore people (Guinea) 
 
1.3 Yeast as model of neurodegenerative diseases 
      Although yeast cell lacks specialized neuronal apparatus, yeast models have been 
extensively used for neurodegenerative diseases and have provided insights in the 
assembly of amyloid fibrils and their toxicity [11]. Being a eukaryote, yeast has several 
Neurodegenerative disease Associated proteins 
Alzheimer’s Disease Aβ(40‐42) 
Frontotemporal dementia  Tau  
Parkinson’s Disease α-Synuclein 
Amyotrophic Lateral Sclerosis TDP-43 
Huntington’s Disease Huntingtin with PolyQ 
Expansion 
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conserved pathways such as cell division, transcriptional regulation, protein targeting 
and cytoskeletal dynamics, similar to mammals [12, 13]. Several prions have been 
identified in yeast (Table 1.3). The extensive understanding of molecular mechanisms 
of yeast prion aggregation has further helped in using yeast as a model for human 
amyloid diseases [9, 13-16]. As heterologous amyloid protein expression in yeast can 
lead to amyloid aggregation, large scale genetic and small molecule screens have been 
attempted for anti-aggregation or anti-toxicity of amyloid proteins from Alzheimer’s, 
Huntington’s and Amyotrophic lateral sclerosis diseases [17-19]. 
Table 1.3: Prions in yeast 
Protein  Function  Prion form 
Sup35 Translation termination [PSI+] 
Ure2 Nitrogen catabolite repression [URE3] 
Rnq1 Unknown [PIN+] 
Swi1 Chromatin remodeling [SWI+] 
 
Yeast prions have been extensively studied for red-white color phenotype. 
Conventionally, the ade1 mutation has been used to score for yeast prion [PSI+] [16, 
20]. If ade1-14 allele is present, which contains a premature stop codon, [psi-] yeast 
appear red on YPD medium due to accumulation of a red intermediate compound in 
the vacuoles. In [PSI+] yeast, partial inactivation of the translation termination 
factor, Sup35 protein, due to sequestration into prion aggregates occurs. This allows 
for read-through of the stop codon in ade1-14 allele, consequently no red intermediate 
pigment accumulates, thus [PSI+] yeast appear white color on YPD (Figure 3) [9]. 
[PSI+] yeast can grow on minimal media without adenine and Sup35-tagged GFP 
forms oligomer aggregates whereas [psi-] yeast cannot grow on minimal media without 
adenine and Sup35-tagged GFP remains diffused [9]. Likewise, a similar color assay 
for [URE3] prion in [PSI+] genetic background has also been developed using ade1 
mutation [21].	
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Figure 3: [PSI+] phenotypes [9] 
1.4 Alzheimer’s disease 
Alzheimer’s disease (AD) is a common neurodegenerative disorder resulting in 
progressive loss of memory and cognitive functions. Accounting for 60-80% of 
dementia, onset of Alzheimer’s commonly begins after 65 years of age[22]. Genetic 
factors contribute in largest to the risk of AD while factors such as head injury, 
hypertension and depression are speculated to play a role in disease onset. Common 
symptoms of AD involve memory loss, disorientation, mood swings, behavioral 
problems and difficulties in language. AD causes large loss in weight and volume of 
the brain in turn reflecting as loss of neuronal processes. AD brain is characterized 
by the accumulation of extracellular amyloid plaques and intracellular neurofibrillary 
tangles composed of aggregated Amyloid β (Aβ) and Tau proteins respectively [23] 
(Figure 4A). With 48 million people reported to suffer from AD, as of 2015, the need 
for understanding and combating toxicity mechanisms has become more relevant. 
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Figure 4: Alzheimer’s pathology and APP processing [23] 
In Alzheimer’s pathology, amyloid beta-42 (Aβ-42) peptide produced from Amyloid 
Precursor Protein forms amyloid plaques and is implicated in progression of disease 
[24]. Amyloid precursor protein (APP) is a single pass transmembrane protein with 
eight isoforms, of which 695 amino acid (aa) is predominant in CNS and 751 aa, 770 
aa are ubiquitous [25]. APP processing plays a crucial role in the AD pathology. 
Three different secretases, α secretase, β secretase and γ secretase vary in the key 
residues they cleave (Image: Qi Chen and David Schubert, Expert reviews in 
Molecular Medicine 2002) (Figure 4B). In cell surface, APP is normally cleaved by α 
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secretase in which case Aβ-42 residues are not formed. However, when APP is cleaved 
by β and γ secretase, variable Aβ polypeptide containing 37-49 residues are formed 
[23] (Figure 4C). 
Accumulation of Aβ in brain is shown to cause aberrant stimulation of Glutamate 
receptors causing excitotoxicity and synaptic depression [26]. Epileptic seizures [27] 
and reduction in Voltage Gated Sodium Channels (VGSC) are also evident in patients 
suffering from AD [28]. Current drug targets for AD include acetylcholine esterase 
whose inhibition can elevate depleted acetylcholine levels in human brain [29], β and 
γ secretase [30, 31] whose inhibition can possibly inhibit Aβ precursor formation, 
modulation of Tau phosphorylation [32, 33] and regulation of apoE4 levels[34].  
When Aβ-42 was expressed in yeast, it was found to form detergent stable oligomers 
suggesting amyloid-like structure and this model has been used for drug screening 
[18, 35]. In the yeast model, when Aβ-42 peptide is directed towards the secretory 
pathway it was found to increase oxidative stress and mitochondrial dysfunction [36]. 
 
1.5 Huntington’s disease  
Huntington’s disease (HD) is a neurodegenerative disorder which predominantly 
affects muscle coordination, personality changes and behavior. HD is an autosomal 
dominant disorder which becomes clinically symptomatic at 35-40 years. Expansion 
of CAG repeats in the gene coding for Huntingtin (HTT) protein encodes an abnormal 
protein which has tendency to aggregate. In Huntington’s disease, mutant extension 
of Poly-Gln(Q) stretches beyond 39 glutamine encoded by huntingtin exon1, have 
been linked to amyloid aggregation and pathogenesis [37].  
Full length HTT protein as well as an amino-terminal HTT exon fragments formed 
undergo proteolysis to generate fragments which can aggregate in nucleus, where it 
causes transcriptional dysregulation and in cytoplasm where it causes mitochondrial 
toxicity, synaptic dysfunction and axonal transport impairment (Figure 5) [37].  
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Figure 5: Pathogenic cellular mechanism of Huntington’s disease[37].  
 
Gene silencing, recovery of mitochondrial function, HTT lowering and 
immunomodulation has been tried as therapeutic strategies for HD. Current drugs in 
clinical trials aim to alleviate the symptoms of motor system dysfunction. 
TetraBenaziene and Cysteamide bitarttrate delayed release capsule are in clinical 
trials which aim to restore muscle coordination [37]. 
A simulative aggregation of Poly-Q-GFP in yeast model also occurs if the number of 
Gln residues are more than 40 and this aggregation is also associated with toxicity 
[38]. Presence of prion-like protein Rnq1 is indispensable for PolyQ toxicity in yeast 
[38, 39]. Further, acceleration of Sup35 fiber formation by heterologous aggregate 
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forming proteins of PolyQ established a link between the prions and Huntington’s[40]. 
Huntingtin Poly-Q aggregation can also alter mitochondrial morphology and 
compromise mitochondrial function, with early alterations in complexes II and III of 
the respiratory chain leading to an increase in ROS production [12, 41]. Yeast models 
of PolyQ tracts have also been widely used as high throughput screen for small 
molecules [42-44] that enhances autophagy and reduce toxicity [45]. 
 
1.6 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder which 
affects the motor neurons, resulting in muscular atrophy, muscle twitching, 
progressive weakness and death within few years. 90% of ALS cases are sporadic 
whereas 10% can be attributed to familial mutations. Trans active response (TAR) 
DNA binding protein (TDP) is a 43 kDa nuclear protein encoded in chromosome 1. 
TDP-43 is a highly conserved protein which contains two RNA recognition motifs 
(RRM 1&2) and a glycine rich C-Terminal region [46] (Figure 6). It is speculated to 
play an important role in transcriptional repression and pre-mRNA splicing. 
 
Figure 6: Domain architecture of TDP-43 [46] 
 
Soluble TDP-43 is ubiquitously present in the nucleus can mislocalise to cytoplasm 
and form toxic inclusions depleting the nuclear pool of TDP-43. Pathological TDP-
43 is hyper phosphorylated, ubiquitinated and cleaved to produce C terminal 
fragments which are capable of aggregating in cytoplasm [47] (Figure 7). Aggregation 
of TAR DNA-binding protein-43 (TDP-43) either of wild-type or familial mutant 
protein sequence into detergent stable structures suggests the presence of amyloid 
nature [48-50]. 
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Figure 7: TDP-43 aggregation [47] 
 
Therapeutic targets of ALS have been to prevent cytoplasmic mislocalisation[51, 52], 
ubiquitination of TDP-43 [53], fragmentation and aggregation of TDP-43 [54] and 
environmental stress [48]. Owing to the complexities of pathways involved, 
therapeutic approaches in clearing TDP-43 and mitigating ALS has not been 
successful. However, there are few drugs which is given to reduce the symptoms, 
especially motor system dysfunction and improve quality of life after ALS. Riluzole 
is an FDA approved drug to reduce damage to motor neurons.  
Strikingly, TDP-43 can also aggregate in the yeast model and shows toxicity. Also it 
shares requirement of several factors such as ataxin-2 homolog, PBP1, modulating its 
aggregation and toxicity thereby suggesting a validity of this yeast model to the 
human ALS [17]. Two ALS mutants R524S or P525L has been reported to show 
increased toxicity in yeast [55]. In yeast, expression of TDP-43 can trigger oxidative 
stress & apoptosis and mitochondrial respiration was found to be an important 
modulator of the cytotoxicity [56]. Unbiased yeast genetic screens have been used to 
identify suppressors of TDP43 toxicity [17]. 
1.7 Hypothesis: Amyloid-induced oxidative stress in yeast 
The host yeast cell used for the over-expression of amyloid proteins Aβ-42-EGFP, 
Poly-Q103-GFP or TDP-43-YFP contained ade1-14 mutant allele which contains a 
premature stop codon in ADE1 gene and is consequently defective in adenine 
biosynthesis that causes red-color phenotype on YPD-agar media due to accumulation 
of a red intermediate metabolite in the vacuoles of these cells [9, 57]. It is known that 
the development of red color in ade1 mutant yeast requires cytoplasmic levels of 
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reduced glutathione which helps in transport of the intermediate metabolite P-
ribosylaminoimidazole carboxylate (CAIR) into vacuoles and the subsequent 
development of color [57, 58]. Here, we hypothesized and examined if amyloid-induced 
oxidative stress in yeast would deplete reduced glutathione levels and thus thwart 
the development of the red color in the ade1 mutant background upon overexpression 
of Aβ-42-EGFP, Poly-Q103-GFP or TDP-43-YFP amyloid proteins (Figure 8) 
 
Figure 8: Hypothesis pathway for amyloid-induced oxidative stress in yeast. 
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Chapter 2 
 
Materials and Methods 
  
 
2.1 Materials 
2, 3, 5-Triphenyl Tetrazolium Chloride, L-ascorbic acid, D-raffinose, D-galactose, 
Ampicillin and Lithium acetate were purchased from Sigma (USA). D-Glucose was 
procured from Amresco (USA). Yeast nitrogen base, yeast extract, peptone, DMSO, 
agar and glass slides were procured from HiMedia (India). Salmon sperm DNA was 
purchased from Invitrogen (USA).  
2.2 Yeast strain and plasmid 
 The [psi-] [pin-] and [psi-] [PIN+] yeast strains were derivatives of 74-D-694 (MATa 
ade1-14 his3-200 ura3-52 leu2-3, 112 trp1-289)[59]. Assays were performed in [psi-] 
[pin-] strain containing pRS416 [60] or pRS416-GAL1p-Aβ-42-EGFP (URA3) (A kind 
gift of Prof. Susan Liebman, University of Nevada, Reno, USA ) or pRS416-GAL1p-
TDP43-YFP (URA3) (Addgene: 27447) and in a [psi-] [PIN+] strain containing 
pRS416-GAL1p-Q103-GFP (URA3) (Addgene: 1186). Yeast strain L-3341, MATα 
ade1-14 leu2-3,112 trp1-289 ura3-52 lys9-A21 erg6::TRP1 [PIN+] [18], a derivative of 
64-D, was a kind gift of Prof. Susan Liebman, University of Nevada, Reno, USA. 
2.3 Bacterial culture media 
Luria Bertani (LB) + Ampicillin media was used for reviving and maintaining the 
bacterial transformants containing pRS416 [60], pRS416-GAL1p-Aβ-42-EGFP 
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(URA3), pRS416-GAL1p-TDP43-YFP (URA3), pRS416-GAL1p-Q103-GFP (URA3) 
plasmids. These plasmids have ampicillin as antibiotic selection marker. LB media 
contains Tryptone (1%), yeast extract (0.5%) and sodium chloride (1%). pH was 
adjusted to 7 using sodium hydroxide and for preparation of solid media 1.5% agar 
was used. Media was autoclaved foe 20 minutes at 121 °C. Media was cooled and 50 
µg/mL ampicillin was added to media.	
2.4 Yeast culture media 
      Standard yeast media and cultivation conditions were used [61]. Yeast cells were 
grown in complex media (YPD) or in a standard synthetic medium lacking a 
particular amino acid and containing either D-glucose (SD) or L-raffinose (SRaf) as 
the sole carbon source. Galactose (2%) was used to over-express GAL1 promoter 
driven genes. Red-white color switch was scored on SRaf-agar lacking Uracil (Ura), 
but containing one-fourth amount of yeast extract and peptone compared to YPD 
and 0.1% galactose (SRaf-agar-Ura+0.1% Gal+¼ YP). Complete loss of mitochondrial 
was scored by lack of growth on complex media containing 2% glycerol as the only 
carbon source (YPG-agar). Effect of ascorbic acid (AA) on red-white color switch 
was scored in SD-agar lacking Uracil (Ura), and containing 10 mM ascorbic acid and 
also added with ¼ YP (SD-agar-Ura+¼ YP+10 mM AA). 
2.5 Plasmid isolation 
Plasmids pRS416, pRS416-GAL1p-Aβ-42-EGFP (URA3), pRS416-GAL1p-TDP43 
YFP (URA3), pRS416-GAL1p-Q103-GFP (URA3) are low copy number yeast 
centromeric plasmids (YCP) under Gal1 promoter.  
Mini Prep  
Plasmids were isolated using GeneJet Thermoscientific kit.  
1. Bacterial transformants were grown in LB-amp broth in rotary shaker at 200 
rpm for 12-16 hours at 37 °C. 
2. Cells were pelleted by centrifuging at 8000 rpm for 2 minutes and the 
supernatant was decanted. 
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3. Cells were resuspended in 250 µL of resuspension solution. Cell suspension 
was transferred to microcentrifuge tube. 
4. 250 µL of lysis solution was added and mixed thoroughly by inverting the 
tube 4-6 times until the solution becomes viscous and slightly clear. 
5. 350 µL of neutralization solution was added and mixed immediately and 
thoroughly by inverting the tube 4-6 times and centrifuged at 10,000 rpm for 
5 minutes to pellet cell debris and chromosomal DNA. 
6. Supernatant was transferred to spin column by pipetting and centrifuged for 
1 minute and flow through was discarded and column was placed back into 
same collection tube. 
7. 500 µL of wash solution was added to column and centrifuged for 1 minute 
and flow through was discarded and step was repeated. 
8. Column was transferred to 1.5 mL microcentrifuge tube and 50 µL of elution 
buffer was added to center of column to elute DNA and incubated for 2 
minutes at room temperature and centrifuged for 2 minutes. 
9. DNA was stored at -20 °C until further use. 
2.6 Transformation of yeast 
Transformation of yeast with plasmids was carried out using the standard Li-Acetate 
method [61]. 
1. Single yeast colony was inoculated in 5 mL YPD and grown overnight broth 
in rotary shaker at 200 rpm at 37 °C. 
2. 0.5 mL of culture was added to 4.5 mL fresh media and grown till it OD660nm 
was approximately 1.0. 
3. Cells were spun down at 3000g for 5 minutes and washed with 10 mL sterile 
water and centrifuged at 3000g for 5 minutes. Pellet was resuspended in 1 mL 
sterile water and transferred to 1.5 mL microcentrifuge tube, spun down and 
resuspended in 1 mL sterile TE/LiAc buffer. 
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4. 250 µL of yeast cells were transformed with 5 µL of plasmid, 5 µL of single 
stranded carrier DNA (10 mg/mL) [boiled and quick chilled on ice] in a 1.5 
mL microfuge tube. 300 µL of sterile PEG was added and mixed thoroughly. 
5. Tube was incubated at 30 °C for 60 minutes with occasional gentle shaking. 
6. 40 µL of DMSO was added and mixed thoroughly. 
7. Heat shock was given at 42 °C for 15 minutes and ice for 2 minutes and spun 
for 1 minute at 14000 rpm to remove supernatant, resuspended in1 mL 1X 
TE. Tube was spun again for 10 second and resuspended in 1 mL 1X TE. 200 
µL was plated on selective media and the plate was incubated at 30 °C until 
colonies appear. 
2.7 Fluorescence microscopy  
For fluorescence microscopy, single colony isolates of yeast plasmid transformants 
were grown overnight at 30 °C in SRaf-Ura broth media. Then, the cells were re-
suspended in fresh media and expressions of TDP-43-YFP, Poly-Q103-GFP or Aβ-42-
EGFP were induced with 2% galactose for 8-24h before harvesting the cells for 
microscopy. Fluorescence was observed under Leica DM-2500 microscope and images 
were acquired using 100x objective lens (oil immersion) in bright field or by using the 
GFP filter and processed using ImageJ software [62].  
2.8 Petite colony assay 
Single cell colony isolates were grown in selective media SRaf-Ura at 30 ºC overnight 
and induced with 2% Gal to express the constructs. After appropriate time, 
appropriate dilutions were made and cells were plated on YPD to observe petite 
colony count. For TDP-43-YFP and PolyQ-103-GFP, the colonies were plated after 
24 hours when aggregates are formed. For Aβ-42-EGFP the colonies were plated after 
8 hours of galactose induction. 
2.9 Red white colony assay 
Single cell colony isolates were grown in selective media SRaf-Ura at 30 ºC overnight 
and induced with 2% Gal to express the constructs. After appropriate time, 
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appropriate dilutions were made and cells were plated on SRaf-Ura+ ¼ YP+0.1% Gal 
to visualize red and white colonies. For TDP-43-YFP and PolyQ-103-GFP, the 
colonies were plated after 24 hours when aggregates are formed. For Aβ-42-EGFP the 
colonies were plated after 8 hours of galactose induction. 
2.10 Triphenyl tetrazolium chloride (TTC) assay 
      2, 3, 5-triphenyltetrazolium chloride (TTC) was used as a color indicator for 
dehydrogenase enzymes. For this,  molten soft agar (1.5%) containing 0.1% of TTC 
was gently poured onto yeast patched pre-grown on SRaf-agar-Ura+0.1% Gal. Plates 
were incubated at 30° C for 2 hours and then imaged [63-65].  
2.11 Growth assay on ascorbic acid 
Yeast cells when grown on media containing small reducing agents can take up the 
reducing agents leading to neutralization of the any cytoplasmic oxidative stress [66]. 
The yeast cells plated in SRaf-agar-Ura+0.1% Gal after the prior overexpression of 
amyloid protein (TDP-43-YFP) with 2% galactose were patched on SD-agar-Ura+ ¼ 
YP and SD-agar-Ura+ ¼ YP+10 mM AA. Cells were serially passaged by patching 
on the same media and examined for color in each passage.  
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Chapter 3 
 
Results and discussion 
   
 
3.1 Aggregation of amyloid proteins causes red to white color switch in ade1 
mutant yeast 
Usually, when Sup35 protein, which is a translation termination factor, is over-
expressed it leads to prion conversion to [PSI+] that partially inactivates Sup35 
protein thereby allowing read-through of the premature stop codon in ade1-14 allele. 
This leads to functional ADE1 protein formation that allows for growth on media 
lacking adenine and also, the red intermediate pigment does not accumulate hence 
the [PSI+] yeast is white on YPD-agar. Thus, this red to white conversion in ade1-14 
allele containing yeast strain (e.g. 74-D-694) upon over-expression of Sup35 protein 
is scored as de novo [PSI+] prion formation [14, 20]. Alternatively, if ade1-14 yeast 
lose their mitochondria and become petite (i.e. [rho-]), they also exhibit red to white 
color phenotype switch on the YPD-agar media [59]. 
When TDP-43-YFP, Aβ-42-EGFP or Poly-Q103-GFP were over-produced from a 
plasmid in a yeast cell using induction of their galactose-inducible promoter by 
addition of 2% galactose in the media, punctate fluorescent foci were formed for each 
of these proteins (Figure 9). This is as expected upon their amyloid-like aggregations 
in the cell which has also been previously established [38, 46, 67]. 
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Figure 9: Aggregation of TDP-43-YFP, Aβ-42-EGFP or Poly-Q103-GFP in yeast cell 
 
When TDP-43-YFP, Aβ-42-EGFP and PolyQ-103-GFP amyloid forming proteins 
were already over-expressed by pre-growth in presence of 2% galactose for 24 h, 8 h 
and 24 h respectively and plated on YPD (Figure 10) to assess the petite cells (which 
has lost mitochondria), we found that only 0.1% of the TDP-43-YFP colonies, 1.3% 
of the Aβ-42-EGFP colonies, & 1.2% of the Poly-Q103-GFP colonies, were found to 
be petites (indicated by black arrow). 
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Figure 10: Petite assay on YPD after amyloid overexpression 
 
Strikingly, when we plated the ade1-14 allele bearing [psi-] [pin-] yeast cells onto SRaf-
agar-Ura+0.1%Gal+ ¼ YP where TDP-43-YFP, Aβ-42-EGFP amyloid forming 
proteins were already over-expressed by pre-growth in presence of 2% galactose, 
~100% (Table 3.1) of colonies from both appeared to have switched to white color 
(Figure 11). The addition of one-fourth yeast extract and peptone (i.e. ¼ YP) 
compared to YPD-agar, allows for red color development in an ade1-14 allele bearing 
yeast cell while also maintaining the plasmid selection. Furthermore, when Poly-Q103-
GFP was over-expressed using 2% galactose in ade1-14 allele bearing [psi-] [PIN+] 
yeast, ~10.9 % (Table 3.1) of colonies for Poly-Q103-GFP appeared white color on 
SRaf-agar-Ura+0.1%Gal+¼ YP plates. 
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Figure 11:  Amyloid protein expression causing red to white color switch in ade1-14 
mutant yeast 
Table 3.1: Red white colony assay in TDP-43-YFP, Aβ-42-EGFP, PolyQ-103-GFP 
On SRaf-Ura+ ¼ YP+ 0.1% Gal 
Amyloid		
Proteins	
Total	
colonies	
	
Red	
colonies	
	
White	
colonies	
	
Pink	
colonies	
	
Percentage	
of	white	
colonies	
	
TDP-43-YFP 
 
1050 0 1050 0 100 
PolyQ-103-GFP 
 
1009 899 110 0 10.9 
Aβ-42-EGFP 
 
289 0 289 0 100 
 
 
When we examined these white color colonies obtained after over-expressions of the 
TDP-43-YFP, Aβ-42-EGFP or Poly-Q103-GFP proteins, for growth on medium lacking 
adenine (SD-agar-ade), the failed to grow. This is as expected, in the view that the 
growth on SD-agar-ade would require that the cells are [PSI+], which in turn requires 
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prior Sup35 over-production [9, 14]. Additionally, when we checked if these white 
colonies were formed by petite cells, by assessing growth on media containing glycerol 
as the only carbon source (YPG-agar) that allows growth of only cells bearing 
functional mitochondria, majority of the white colonies showed positive growth on 
YPG-agar (Figure 12).  
 
Figure 12: White color switch is not due to complete mitochondrial loss. 
 
In the view that majority of the white colonies were neither [PSI+] nor petites, we set 
forth to examine the mechanistic cause for the red to white color switch. For this, as 
the formation of the intermediate metabolite due to the pre-mature nonsense 
mutation in ade1-14 allele is not expected to be hindered in a non-[PSI+] cell, we 
reasoned that possibly the development of the red color from this intermediate 
(CAIR) is instead being interfered with, upon the over-expressions and cellular 
aggregations of these TDP-43-YFP, Aβ-42-EGFP or Poly-Q103-GFP amyloid-forming 
proteins. It is previously known that the aggregation of these amyloid-like proteins 
can cause general cytotoxicity by several mechanisms such as impairing protein 
homeostasis, over-engaging cellular chaperones or by causing oxidative stress etc. [38, 
46, 68]. Also, it has been previously demonstrated that reduced glutathione-mediated 
transport of the intermediate metabolite, CAIR, to the vacuoles in an ade1 mutant 
yeast, is required for the development of the red color [57]. Thus, we hypothesized 
that possibly the accumulation of these amyloid aggregates leads to oxidative stress 
that could deplete the levels of reduced glutathione by oxidizing it. In turn, even after 
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being synthesized the intermediate metabolite in the ade1 mutant yeast would not 
be transported to the vacuoles and thus the red color would not develop thereby 
imparting white color to the host yeast. 
3.2 Red to white color switch is reversible  
When the yeast cells SRaf-Ura+0.1% Gal were passaged on YPD, SD-Ura+1/4YP 
and SRaf-Ura+0.1% Gal+1/4 YP, after first passage white colonies from TDP-43-
YFP, Poly-Q103-GFP turned 100% red on YPD, 100% white on SRaf-Ura+0.1% 
Gal+1/4 YP whereas in SD-Ura+1/4 YP, white colonies turned pink. In Aβ-42-
EGFP, after first passage on SD-Ura + ¼ YP, 87.5% cells turned pink (Table 3.2). 
If the white color switch was due to induction of oxidative stress by amyloid 
aggregation and not due to a suppressor genetic mutation(s) or reversion of the ade1-
14 allele to wild-type ADE1 allele, the yeast would be expected to switch back to red 
color once the oxidizing environment is over. To check this, we examined if 
sequentially passaging these white colonies on SD-agar-Ura+¼ YP, where the 
expressions of these amyloid forming proteins would be turned-off, leads to reversion 
to the red color phenotype. Indeed, we observed that after three passages on SD-agar-
Ura+¼ YP, the white cells returned back to the red color phenotype (Figure 13). 
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Table 3.2: Red white colony count after first passage on different media 
 
Amyloids	 Media	 Red	 White	 Pink	 Percentage	
TDP-43-YFP 
 
White 
 
(22 colonies) 
YPD 22 0 0 100% Red 
 
SD-Ura + ¼ YP 0 16 6 27% Pink, 
72.7% white 
 
SRaf-Ura + ¼ YP +0.1% 
Gal 
0 22 0 100% white 
 
PolyQ-103-
GFP 
 
Red 
 
(16 colonies) 
YPD 16 0 0 100% Red 
 
SD-Ura + ¼ YP 16 0 0 100% Red 
 
SRaf-Ura + ¼ YP +0.1% 
Gal 
0 0 16 100% Pink 
 
PolyQ-103-
GFP 
 
White 
 
(15 colonies) 
YPD 15 0 0 100% Red 
 
SD-Ura + ¼ YP 0 15 0 100% white 
 
SRaf-Ura + ¼ YP +0.1% 
Gal 
0 15 0 100% white 
 
Aβ-42-EGFP 
 
White 
 
(16 colonies) 
YPD 16 0 0 100% Red 
 
SD-Ura + ¼ YP 16 0 0 100% Red 
 
SRaf-Ura + ¼ YP +0.1% 
Gal 
0 2 14 87.5% Pink, 
12.5% white 
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Figure 13: White color switch is reversible 
In contrast, when the white cells were passaged similarly on media that allowed for 
even milder continued expression of these amyloid proteins using 0.1% galactose (on 
SRaf-agar-Ura + 0.1% Gal+¼YP), the cells retained their acquired white color 
phenotype (Figure 12). Additionally, the acquired white phenotype rapidly converted 
to red color even upon the first passage on the complex complete media YPD-agar 
possibly due to its greater buffering ability against oxidative stress (Figure 12). 
 
3.3 White yeast colonies exhibit signs of oxidative stress 
While the above data are consistent with presence of oxidizing environment in white 
colonies obtained after over-expressions of the TDP-43-YFP, Aβ-42-GFP or Poly-
Q103-GFP amyloid-forming proteins, we further attempted to experimentally establish 
the presence of oxidative stress in these cells. It is known that oxidative stress can 
damage mitochondria thereby leading to its leakiness & causing enhanced release & 
secretion of mitochondrial redox enzymes such as dehydrogenases [65].Therefore, we 
assayed the relative levels of available dehydrogenases by reaction with a probe 
organic substrate 2,3,5-triphenyl tetrazolium chloride which develops red color after 
being acted upon by dehydrogenase enzymes [63-65, 69]. Indeed, when tested directly 
on patches of yeast cells over-expressing either the TDP-43-YFP or a control empty 
vector, the amyloid-expressing cells developed red color relatively faster and also with 
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higher intensity (Figure 14). This data confirms elevated presence of dehydrogenases 
and are suggestive of presence of mitochondrial damage. 
 
Figure 14: TTC method for assessment of presence of mitochondrial damage 
 
Furthermore, if the white yeast cells have oxidizing cellular environment, growth on 
media containing a reducing agent, such as ascorbic acid, would be expected to restore 
the red phenotype back. Reducing agent could prevent the oxidation of the reduced 
glutathione and allow for the transport of the adenine biosynthesis intermediate 
metabolite to the vacuoles thereby helping in red color development. Indeed, when 
we plated the white cells on medium containing 10 mM ascorbic acid, the color 
transitioned to red thereby corroborating our assumption of presence of oxidizing 
stress in the amyloid-expressing cells (Figure 15). In controls, when we likewise plated 
[PSI+] cells on this ascorbic acid medium, the cells continued to retain their white 
color phenotype.  
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Figure 15: Growth on ascorbic assay to assess oxidative stress 
This is consistent with the expectations as the [PSI+] cells do not produce the adenine 
biosynthesis intermediate metabolite and therefore cannot develop the red color even 
if the cytoplasm becomes more reducing in nature thereby the elevating reduced 
glutathione cytoplasmic levels. Notably, in presence of ascorbic acid, the overall 
intensity of the red color was relatively less, possibly due to other pleiotropic effects 
of ascorbic acid on the yeast physiology.   
3.4 Amyloid-induced red to white switch also occurs in erg6Δ ade1-14 double 
mutant yeast 
Yeast models of amyloid aggregation have been previously utilized to screen for drug-
like anti-aggregation molecules such as against Aβ-42 aggregation [18]. The designed 
red-white assay here would be easily applicable for such screening of anti-amyloid 
small molecules due to its simplicity. As yeast cell wall is generally impervious to 
small drug-like molecules, we examined if the red-white color assay can also be 
recapitulated in an erg6Δ yeast which, due to defective ergosterol biosynthesis, 
increases the permeability of the yeast cell wall [57, 70, 71]. For this, we transformed 
an erg6Δ derivative yeast of 64-D strain, which also contains the ade1-14 mutant 
allele, with the galactose inducible TDP-43-YFP expression plasmid. Alike in the 74-
D694 yeast strain containing the ade1-14 allele, over-expression of TDP-43-YFP in 
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the 64-D yeast with erg6Δ mutation also lead to red to white color switch (Figure 
16).  
 
Figure 16: Red to white color switch in erg6Δ ade1-14 yeast 
Furthermore, the color switch was also reversible and dependent on the sustained 
expression of the amyloid similar to the observations in the 74-D-694 background 
thereby validating the amyloid-induced red to white color switch model in the erg6Δ 
ade1-14 yeast (Figure 16). 
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Chapter 4 
 
Conclusion 
  
In this work, amyloid proteins TDP-43-YFP, Aβ-42-GFP or Poly-Q103-GFP inducing 
oxidative stress in yeast models of Amyotrophic Lateral sclerosis (ALS), Alzheimer’s 
and Huntington’s was studied. Oxidative stress caused by the amyloids was correlated 
with the phenotypic color switch in ade1-14 and erg6Δ ade1-14 double mutant yeast. 
The observed phenotypic change was reversible if the expression of amyloid proteins 
in yeast was stopped. Also, this colour change was reversed by reducing the oxidative 
stress by providing reducing environment to yeast cell with reducing agents such as 
ascorbic acid. Mitochondrial damage was assessed by the amount of dehydrogenase 
present in the yeast cells expressing TDP-43 using TTC assay and it was found that 
even though there is no significant number of petites (yeast cells without functional 
mitochondria), amyloid induced mitochondrial damage is observed in yeast system. 
From these observations, we correlated the white colonies in ade1-14 yeast after the 
expression of amyloid proteins to be a marker of protein aggregation and oxidative 
stress caused by amyloids. The observation that this color assay can respond to any 
oxidative stress-inducing amyloid, can make it a general and versatile tool for anti-
amyloid and anti-oxidative stress drug screening in the yeast model. 
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